

A man presenting headache and photophobia while receiving BEP chemotherapy

Antonia Digkليا, Dominik Berthold, Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Univer sitaire Vaudois, Lausanne

Keywords: germ cell cancer, thrombo-embolism, chemotherapy, cerebral sinus thrombosis

A 31-year old man with a right testicular mass was evaluated at the urology department. Scrotal ultrasound revealed a right hypervascularized testicular mass of 8,5cm. Alpha fetoprotein and bHCG were elevated at 821kU/l ($N < 5kU/l$) and 8200U/l ($N < 5U/l$) respectively. The thoracic-abdominal computed tomography scan showed an enlarged retroperitoneal lymph node of 32mm (Figure 1). The past medical history was notable for a right orchidopexie at age of 5 years and an Asperger syndrome, an autism spectrum disorder that is characterized by significant difficulties in social interaction, along with restricted and repetitive patterns of behavior and interests. It differs from other autism spectrum disorders by its relative preservation of linguistic and cognitive development. The patient underwent an inguinal and scrotal orchidectomy. Tumor markers descended significantly but did not normalize; the patient was considered a stage II, «good prognosis» metastatic germ cell tumor (IGCCCG prognostic grouping classification) and scheduled according to the European Consensus Guideline for 3 cycles of bleomycin, etoposide and cisplatin (BEP)^{1,2}. Just before the 2nd cycle, the patient complained about nausea and headache

with photophobia. Physical exam was unremarkable with the exception of moderate scleral injection. A viral infection was suspected. These symptoms improved during the second course of chemotherapy but the patient presented a generalized seizure while leaving the hospital on day 5. Urgent CT and MRI scan showed a cerebral sinus thrombosis and ruled out brain metastasis (Figure 2). No smoking history or cardiovascular risk factors were identified and further investigations ruled out heart disease and coagulopathy. Anticoagulation and anti-convulsant treatments were introduced. The patient completed his chemotherapy at full dose archiving complete remission.

Discussion

BEP is the cornerstone in the management of metastatic germ cell tumors. Acute toxicities are tiredness, leucopenia, nausea, alopecia, neuropathie and kidney deficiency due to cisplatin. Thrombotic occlusions of peripheral arteries during chemotherapy have been reported in a number of patients with germ cell cancer.³⁻⁶ Only few cases with cerebral venous sinus thrombosis during chemotherapy have been reported and none to our knowledge did involve patients with testicular germ cell tumor.⁷ Cerebral vein and dural sinus thrombosis (CVT) are less common than most other types of stroke. Large sinuses such as the superior sagittal sinus are most frequently involved. Extensive collateral circulation within the cerebral venous system allows for a significant degree of compensation in the early stages of thrombus formation. Systemic inflammatory diseases and inherited as well as acquired coagulation disorders are frequent causes, although in up to 30% of cases no underlying cause can be identified. The spectrum of clinical presentations ranges from headache with papilloedema to focal deficit, seizures and coma, and it's more common in women than men, with a female to male ratio of 3:1.




Figure 1: Retro-peritoneal lymph node methastasis.




Figure 2: Cerebral sinus thrombosis

Cardiovascular risk factors, such as smoking and pre-existing arterial disease, are frequently mentioned as risk factors for the development of thromboembolic events in cancer patients. Furthermore, several other mechanisms have been hypothesized, including high dose corticosteroids, cisplatin-related, several mutations (factor V Leiden and prothrombin).^{8,9}

It is known that high doses of corticosteroids (≥ 80 mg dexamethasone per cycle) are independent risk factors for the development of thromboembolic events in germ cell cancer patients undergoing chemotherapy. This is in agreement with several reports about the hypercoagulable state and the occurrence of thromboembolic events of patients with Cushing's syndrome.¹⁰ Various mechanisms contribute to the hypercoagulability induced by corticosteroids: inhibition of blood fibrinolytic activity and decrease platelet count and levels of the clotting factor VIII/von Willebrand factor complex. Moreover, corticosteroids are known to decrease cerebral blood flow by their direct vasoconstrictive effect on cerebral blood vessels, increase blood pressure, and decrease the clearance rate of activated clotting factors by reticuloendothelial blockade.

Secondary TE events constitute well recognized complication of chemotherapy.¹¹ Cisplatin has been implicated for the occurrence of venous and arterial thrombotic complications in patients with disseminated germ cell cancer. There are a lot of hypothesis about the mechanism of cisplatin-induced TE events, including cisplatin-related hypomagnesemia, drug-induced damage of the vascular endothelium which would activate the coagulation cascade, and elevation of von Willebrand factor plasma levels.¹² Cisplatin is thought to initiate degenerative processes of vessel walls, thus causing occlusive vascular disease in the long run. All types of arteries may be involved, and there is sound evidence for an excess of myocardial infarctions, arterial hypertension, and cerebral strokes. Recently, a meta-analysis showed that cardiovascular complications secondary to cisplatin-based chemotherapy may also occur early during the application of systemic therapy or immediately thereafter. Such complications from cisplatin-based chemotherapy have been encountered in several malignancies, but patients with germ-cell tumors are at higher risk for thrombo-embolic events than patients with non germ-cell tumors while on cisplatin-based chemotherapy and the risk can be predicted by the serum lactate dehydrogenase (LDH) levels and the body surface area.¹³

We reported a young patient with a cerebral venous sinus thrombosis during chemotherapy for germinal cancer. He had no prior history of vascular thrombosis. Investigation for systemic vasculitis, disseminated intravascular coagulation, anticardiolipin antibodies and thrombophilia was negative and the only risk factor for CST identified was the chemotherapy regimen. Although clinical thrombo-

embolism occurs in as many as 11 percent of patients with cancer and is the second leading cause of death in patients with overt malignant disease, there is not enough information available at this time to recommend for or against the use of anticoagulation to prevent VTE in ambulatory cancer patients receiving chemotherapy. The 2007 ASCO guidelines, the 2008 ACCP guidelines, and a 2009 Consensus Statement of major guidelines panels do not recommend routine VTE prophylaxis in ambulatory patients with cancer, except for those with multiple myeloma receiving thalidomide or lenalidomide and chemotherapy or dexamethasone.¹⁴⁻¹⁶ Randomized studies comparing low molecular weight (LMW) heparin to placebo in cancer patients receiving chemotherapy are ongoing, but results from a large randomized controlled study indicated that use of the LMW heparin nadroparin did not significantly improve median overall survival in 503 patients with advanced cancer (prostate, pancreas, non-small cell lung cancer) over those not receiving this agent (13.1 versus 11.9 months, respectively)¹⁷.

Clinicians treating patients with germ cell cancers should be aware about the increased thromboembolic event rate and should have a low threshold to use prophylactic low molecular weight heparin¹⁸.

Literature

1. Krege S, Beyer J, Souchon R, et al: European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. *European urology* 53:478-96, 2008
2. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* 15:594-603, 1997
3. Weijl NI, Rutten MF, Zwinderman AH, et al: Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* 18:2169-78, 2000
4. Dieckmann KP, Gerl A, Witt J, et al: Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. *Annals of oncology: official journal of the European Society for Medical Oncology / ESMO* 21:1607-11, 2010
5. Dieckmann KP, Gehrckens R: Thrombosis of abdominal aorta during cisplatin-based chemotherapy of testicular seminoma - a case report. *BMC cancer* 9:459, 2009
6. Cheng E, Berthold DR, Moore MJ, et al: Arterial thrombosis after cisplatin-based chemotherapy for metastatic germ cell tumors. *Acta oncologica* 48:475-7, 2009
7. Karam C, Koussa S: Cerebral dural sinus thrombosis following cisplatin chemotherapy. *Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia* 15:1274-5, 2008
8. Bertina RM, Koeleman BP, Koster T, et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature* 369:64-7, 1994
9. Poort SR, Rosendaal FR, Reitsma PH, et al: A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood* 88:3698-703, 1996

10. Van Zaane B, Nur E, Squizzato A, et al: Hypercoagulable state in Cushing's syndrome: a systematic review. *The Journal of clinical endocrinology and metabolism* 94:2743-50, 2009

11. Blom JW, Doggen CJ, Osanto S, et al: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. *JAMA: the journal of the American Medical Association* 293:715-22, 2005

12. Licciardello JT, Moake JL, Rudy CK, et al: Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. *Oncology* 42:296-300, 1985

13. Piketty AC, Flechon A, Laplanche A, et al: The risk of thromboembolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. *British journal of cancer* 93:909-14, 2005

14. Lyman GH: Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. *Cancer* 115:5637-50, 2009

15. Kucher N, Spirk D, Baumgartner I, et al: Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWISS Venous Thromboembolism Registry (SWIVTER). *Annals of oncology: official journal of the European Society for Medical Oncology / ESMO* 21:931-5, 2010

16. Lyman GH: Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. *Cancer* 117:1334-49, 2011

17. Van Doornaal FF, Di Nisio M, Otten H-M, Richel DJ, Prins M, Buller HR: Randomized Trial of the Effect of the Low Molecular Weight Heparin Nadroparin on Survival in Patients With Cancer. Published online before print April 18, 2011, doi: 10.1200/JCO.2010.31.9293 *JCO* May 20, 2011 vol. 29 no. 15 2071-2076

18. Khorana AA: Cancer and thrombosis: implications of published guidelines for clinical practice. *Annals of oncology: official journal of the European Society for Medical Oncology / ESMO* 20:1619-30, 2009

Correspondence:

Dr. med. Antonia Digklier
Centre Pluridisciplinaire d'Oncologie
Centre Hospitalier Universitaire Vaudois
Rue de Bugnon 46
CH-1011 Lausanne
antonia.digklier@chuv.ch

NOUVEAUTÉ: Atelier interprofessionnel de psycho-oncologie en français

La Ligue suisse contre le cancer (LSC) et la Société suisse de psycho-oncologie (SSPO) proposent depuis plusieurs années une formation continue interprofessionnelle de psycho-oncologie en langue allemande. Cette année, pour la première fois, un atelier interprofessionnel est proposé en français. L'objectif: sensibiliser différents groupes professionnels actifs dans les soins oncologiques de base aux multiples aspects de la psycho-oncologie, tout en leur permettant d'acquérir de nouvelles connaissances et de désamorcer certaines difficultés. Il s'agit d'offrir aux personnes atteintes de cancer et à leurs proches un soutien psychosocial de qualité.

Intitulé «Introduction à la psycho-oncologie: éléments clés», l'atelier abordera des thèmes comme l'adaptation des patients à la maladie, les troubles psychiatriques les plus fréquents, les bases de la communication avec le patient ainsi que les éléments clés des interventions psychothérapeutiques.

Lieu et date

Le 8 septembre 2011, de 8 h 30 à 16 h 45 au Centre hospitalier universitaire vaudois (CHUV), Rue du Bugnon 21, Lausanne.

Chargés de cours

Prof. Dr med. Friedrich Stiefel, psychiatre et chef du Service de psychiatrie de liaison, CHUV.
Sonia Krenz, psychologue associée (FSP), Service de psychiatrie de liaison, CHUV.

Public cible

L'atelier s'adresse à un public interdisciplinaire composé de différents spécialistes dans le domaine de l'oncologie: psychologues, médecins, travailleurs sociaux, spécialistes en soins infirmiers, théologiens, etc.

Conditions d'admission

Tous les participants doivent travailler dans un service ou une consultation ambulatoire d'oncologie, en contact direct avec des personnes atteintes d'un cancer.

Coûts

Frais d'inscription: CHF 400.-.

Contact

Ligue suisse contre le cancer, Valentina Celio Moser, case postale 8219, 3001 Berne
tél. 031 389 91 26, fax 031 389 91 60, valentina.celio@liguecancer.ch